These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16330427)

  • 1. Waldenström's macroglobulinemia and bortezomib.
    Leblond V
    Haematologica; 2005 Dec; 90(12):1589A. PubMed ID: 16330427
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
    Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib and Waldenstrom's macroglobulinemia.
    Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
    Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
    Focosi D
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):E16-7. PubMed ID: 19717373
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of proteasome inhibition in Waldenström's macroglobulinemia.
    Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
    Laubach JP; Mitsiades CS; Roccaro AM; Ghobrial IM; Anderson KC; Richardson PG
    Leuk Lymphoma; 2009 May; 50(5):694-702. PubMed ID: 19452315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
    Noronha V; Fynan TM; Duffy T
    J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
    [No Abstract]   [Full Text] [Related]  

  • 17. Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
    Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe intestinal vasculitis in a patient under treatment with bortezomib.
    Mangiacavalli S; Zappasodi P; Castagnola C; Astori C; Varettoni M; Lazzarino M; Corso A
    Ann Hematol; 2007 Dec; 86(12):923-4. PubMed ID: 17641890
    [No Abstract]   [Full Text] [Related]  

  • 20. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.